Education
About Us
Working with TipRanks
Follow Us
BioMark Diagnostics (TSE:BUX)
:BUX
RESEARCH TOOLSreports
BUX Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.18 - C$0.31
Previous CloseN/A
Volume0.00
Average Volume (3M)8.25K
Market Cap
C$22.72M
Enterprise ValueC$18.64M
Total Cash (Recent Filing)C$88.58K
Total Debt (Recent Filing)C$546.53K
Price to Earnings (P/E)―
Beta-0.46
Next Earnings
Jul 09, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding90,886,230
10 Day Avg. Volume4,150
30 Day Avg. Volume8,250
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)146.68
Price to Cash Flow (P/CF)-14.20
P/FCF Ratio349.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
BioMark Diagnostics News
PremiumCompany Announcements
BioMark’s Breakthrough in Breast Cancer Diagnosis
PremiumCompany Announcements
BioMark Advances in Breast Cancer Detection Technology
PremiumCompany Announcements
BioMark Advances Cancer Detection with Biomarker Study
PremiumCompany Announcements
BioMark Diagnostics Advances Lung Cancer DetectionPremiumCompany Announcements
BioMark Diagnostics Unveils Cancer Detection Tech at Global Conference---
Options Prices
Currently, No data available
---
Ownership Overview
55.87% Insiders
―
Mutual Funds
― Other Institutional Investors
44.13% Public Companies and
Individual Investors
BUX FAQ
What was BioMark Diagnostics’s price range in the past 12 months?
BioMark Diagnostics lowest stock price was C$0.18 and its highest was C$0.30 in the past 12 months.
What is BioMark Diagnostics’s market cap?
BioMark Diagnostics’s market cap is C$22.72M.
When is BioMark Diagnostics’s upcoming earnings report date?
BioMark Diagnostics’s upcoming earnings report date is Jul 09, 2025 which is in 74 days.
How were BioMark Diagnostics’s earnings last quarter?
BioMark Diagnostics released its earnings results on Mar 01, 2025. The company reported -C$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.004.
Is BioMark Diagnostics overvalued?
According to Wall Street analysts BioMark Diagnostics’s price is currently Overvalued.
Does BioMark Diagnostics pay dividends?
BioMark Diagnostics does not currently pay dividends.
What is BioMark Diagnostics’s EPS estimate?
BioMark Diagnostics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioMark Diagnostics have?
BioMark Diagnostics has 90,886,230 shares outstanding.
What happened to BioMark Diagnostics’s price movement after its last earnings report?
BioMark Diagnostics reported an EPS of -C$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BioMark Diagnostics?
Currently, no hedge funds are holding shares in TSE:BUX
---
Company Description
BioMark Diagnostics
BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.
---
Technical Analysis
---